SpringerProtocols: Abstract: 7. Quantifying Residual Leukemia by “Clone-Specific” Polymerase Chain Reaction

7. Quantifying Residual Leukemia by “Clone-Specific” Polymerase Chain Reaction

By: Michael J. Brisco²

Abstract

Full Text

Download PDF (167K)

Molecular biology tests can quantify extremely low levels of cancer cells, provided that a genetic marker for the cancer is known. Acute lymphoblastic leukemia (ALL) exhibits many genetic abnormalities, but most are uncommon or technically difficult to use as markers for sensitive quantification. We therefore use the leukemia clone’s rearranged immunoglobulin heavy-chain (IgH) gene as a clonal marker (1,2). A very sensitive, quantitative polymerase chain reaction (PCR) test with “clone-specific” primers can be developed for 60–70% of B-lineage ALLs (see Fig. 1 ).

MediaObjects/978-1-59259-074-2_7_Fig1_HTML.jpg

Fig. 1. Strategy for quantifying residual disease.

Affiliation(s): (2) Department of Haematology, Flinders University of South Australia and Flinders Medical Center, Bedford Park, South Australia

Book Title: Hematologic Malignancies: Methods and Techniques

Series: Methods in Molecular Medicine | Volume: 55 | Pub. Date: Nov-30-2000 | Page Range: 133-156 | DOI: 10.1385/1-59259-074-8:133

Subject: Molecular Medicine

References

Download References

1.	Brisco, M. J., Tan, L. W., Orsborn, A., and Morley, A. A. (1990) Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br. J. Haematol. 75, 163–167.

2.	Sykes, P. J., Neoh, S.-H., Brisco, M. J., Hughes, E., Condon, J., and Morley, A. A. (1992) Quantitation of Targets for the polymerase chain reaction by use of limiting dilution. Biotechniques 13, 444–449.

3.	Brisco, M. J., Condon, J., Hughes, E., Neoh, S.-H., Sykes, P. J., Seshadri, R., Toogood, I., Waters, K., Tauro, G., Ekert, H., and Morley, A. A. (1994) Outcome prediction of outcome in childhood acute lymphoblastic leukaemic by molecular quantification of residual disease at the end of induction. Lancet 343, 196–200.

4.	Brisco, M. J., Hughes, E., Neoh, S.-H., Sykes, P. J., Bradstock, K., Enno, A., Szer, J., McCaul, K., and Morley, A. A. (1996) Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukaemia. Blood 87, 5251–5256.

5.	Brisco, M. J., Sykes, P. J., Dolman, G., Neoh, S.-H., Hughes, E., Peng, L. M., Tauro, G., Ekert, H., Toogood, I., Bradstock, K., Morley, A. A., (1997) Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia Leukemia 11, 1497–1500.

6.	Steenbergen, E. J., Verhagen, O. J. H. M., Van Leeuwen, E. F., Van den Berg, H., Behrendt H., Slater, R. M., von dem Borne, A. E. G., and van der Schoot, C. E. (1995) Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukaemia. Leukemia 9, 1726–1734.

7.	Wasserman, R., Galili, N., Ito, Y., Silber, J. H., Reichard, B. A., Shane, S., Womer, R. B., Lange, B., and Rovera, G. (1992) Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 10, 1879–1888.

8.	Nizet, Y., van Daele, S., Lewalle, P., Vaerman, J. L., Philippe, M., Vermylen, C., Cornu, G., Ferrant, A., Michaux, J. L., and Martiat, P. (1993) Long term follow-up of residual disease in acute lymphoblastic leukaemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 82, 1618–1625.

9.	Roberts, W. M., Estrov, Z., Ouspenskaia, M. V., Johnston, D. A., McClain, K. L., and Zipf, T. F. (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 336, 317–323.

10.	d’Auriol, L., Macintyre, E,. Galibert, F., and Sigaux, F. (1989) In vitro amplification of T cell γ gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias. Leukemia 3, 155–158.

11.	Hansen-Hagge, T. E., Yokota, S., and Bartram, C. R. (1989) Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor δ chain sequences. Blood 74, 1762–1767.

12.	Jonsson, O. G., Kitchens, R. L., Scott, F. C., and Smith, R. G. (1990) Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. Blood 76, 2072–2079.

13.	Nizet, Y., Martiat, P., Vaerman, J. L., Philippe, M., Wildmann, C., Staelens, J. P., Cornu, G., Ferrant, A., Michaux, L. J., and Sokal, G. (1991) Follow up of residual disease (MRD) in B lineage acute leukemias using a simplified PCR strategy: evolution of MRD rather that its detection is correlated with clinical outcome. Br. J. Haematol. 79, 205–210.

14.	Yamada, M., Hudson, S., Tournay, O., Bittenbender, S., Shane, S. S., Lange, B., Tsujimoto, Y., Caton, A. J., and Rovera, G. (1989) Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc. Natl. Acad. Sci. USA 86, 5123–5127.

15.	Tycko, B., Palmer, J. D., Link, M. P., Smith, S. D., and Sklar, J. (1989) Polymerase chain reaction amplification of rearranged antigen receptor genes using junction-specific oligonucleotides: possible application for detection of minimal residual disease in acute lymphoblastic leukaemia. Cancer Cells 7, 47.

16.	Seriu, T., Yokota, S., Nakao, M., Misawa, S., Takaue, Y., Koizumi, S., Kawai, S., and Fujimoto, T. (1995) Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumour cells in peripheral blood stem cells for autotransplantation. Leukemia 9, 615–623.

17.	Zwicky, C. S., Maddocks, A. B., Andersen, N., and Gribben, J. G. (1996) Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin’s lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 88, 3314–3322.

18.	Henry, J. M., Sykes, P. J., Brisco, M. J., To, L. B., Juttner, C. A., and Morley, A. A. (1996) Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br. J. Haematol. 92, 614–619.

19.	Kornhuber, B., Ebener, U., Niegemann, E., and Wehner, J. (1997) Minimal residual disease in leukemia in children. Ann. N. Y. Acad. Sci. 824, 65–70.

20.	Sykes, P. J. and Morley, A. A. (1995) Limiting dilution polymerase chain reaction, in Reverse transcriptase PCR (Larrick, J. W. and Siebert, P. D., eds.), Ellis Horwood, Hemel Hempstead, Herts, UK, pp. 150–165.

21.	Jeffreys, A. J., Wilson, V., Neumann, R., and Keyte, J. (1988) Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting ingle cells. Nucleic Acids Res. 16, 10,953–10,971.

22.	Chou, Q., Russell, M., Birch, D. E., Raymond, J., and Bloch, W. (1992) Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplification. Nucleic Acids Res. 20, 1717–1723.

23.	Taswell, C. (1981) Limiting dilution assays for the determination of immunocompetent cell frequencies. J. Immunol. 126, 1614–1619.

24.	Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th ed. National Institutes of Health, Bethesda, MD., pp. 1938–1946 and 1982-1983. The Kabat database (http://immuno.bme.nwu.edu/) may contain more recent additions.

25.	Marshall, G. M., Kwan, E., Haber, M., Brisco, M. J., Morley, A. A., Toogood, I., Waters, K., Tauro, G., Ekert, H., and Norris, M. D. (1995) Characterisation of clonal immunoglobulin heavy chain and T cell receptor γ gene rearrangements during progression of childhood acute lymphoblastic leukemia. Leukemia 9, 1847–1850.

26.	Norris, M. D., Kwan, E., Haber, M., and Marshall, G. M. (1995) Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJ_H primers. Leukemia 9, 1779–1782.

27.	Wan, J. H., Sykes, P. J., Orell, S. R., and Morley, A. A. (1992) Rapid method for detecting monoclonality in B cell lymphoma in lymph node aspirates using the polymerase chain reaction. J. Clin. Pathol. 45, 420–423.

28.	Ichihara, Y., Matsuoka, H., and Kurosawa, Y. (1988) Organization of human immunoglobulin heavy chain diversity loci. EMBO J. 7, 4141–4150.

29.	Yamada, M., Wasserman, R., Reichard, B. A., Shane, S., Caton, A. J., and Rovera, G. (1991) Preferential utilization of specific immunogloublin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. J. Exp. Med. 173, 395–407.

Comments (Loading...)

Post comment/View all comments